Literature DB >> 11782066

Cure model analysis in cancer: an application to data from the Children's Cancer Group.

Richard Sposto1.   

Abstract

The most commonly used statistical methods for evaluating treatment or prognostic effects on cancer outcome--the logrank test and Cox regression analysis--rely on the proportional hazards (PH) assumption in that they have maximal power in this circumstance. Implicitly, these methods emphasize covariate effects on failure times rather than their effects on the proportion of long-term survivors ('cures'), which may be of equal or primary interest. In paediatric cancer, treatment has progressed dramatically in recent decades, and in many diagnoses cures are obtained in a large fraction of patients. A primary focus of clinical research is therefore the achievement of cure. Parametric cure model (PCM) analysis, introduced 50 years ago, is arguably better suited to the analytic requirements of clinical research in paediatric and other cancers where cure is achieved. In this paper two classes of PCMs are described and used to analyse examples from the Children's Cancer Group. These are compared to analyses using Cox regression analysis. Results from PCM analyses are similar or identical to Cox regression analysis when the PH assumption is appropriate. When it is not, PCMs can provide a coherent way to investigate and report covariate effects on the proportion cured separately from their effect on time to failure. Despite their reliance on explicit parametric forms, PCMs often provide a good description of cancer outcome, and are insensitive to lack of fit provided that follow-up is sufficient. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 11782066     DOI: 10.1002/sim.987

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  14 in total

1.  Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.

Authors:  Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2019-10-24       Impact factor: 44.544

3.  Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.

Authors:  Peter G Steinherz; Nita L Seibel; Harland Sather; Lingyun Ji; Xinxin Xu; Meenakshi Devidas; Paul S Gaynon
Journal:  Leukemia       Date:  2019-02-28       Impact factor: 11.528

4.  Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States.

Authors:  A Lindsay Frazier; Juliet P Hale; Carlos Rodriguez-Galindo; Ha Dang; Thomas Olson; Matthew J Murray; James F Amatruda; Claire Thornton; G Suren Arul; Deborah Billmire; Furqan Shaikh; Farzana Pashankar; Sara Stoneham; Mark Krailo; James C Nicholson
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

5.  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.

Authors:  Kenneth J Cohen; Ian F Pollack; Tianni Zhou; Allen Buxton; Emiko J Holmes; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Ronald L Hamilton; Robert S Lavey; Richard L Heideman
Journal:  Neuro Oncol       Date:  2011-03       Impact factor: 12.300

6.  Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial.

Authors:  Eni Musta; Nan van Geloven; Jakob Anninga; Hans Gelderblom; Marta Fiocco
Journal:  BMJ Open       Date:  2022-05-10       Impact factor: 3.006

Review 7.  Children's Oncology Group's 2013 blueprint for research: rare tumors.

Authors:  Carlos Rodriguez-Galindo; Mark Krailo; Lindsay Frazier; Murali Chintagumpala; James Amatruda; Howard Katzenstein; Marcio Malogolowkin; Logan Spector; Farzana Pashankar; Rebecka Meyers; Gail Tomlinson
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population.

Authors:  Urban Hellman; Flora Alarcon; Hans-Erik Lundgren; Ole B Suhr; Catherine Bonaiti-Pellié; Violaine Planté-Bordeneuve
Journal:  Amyloid       Date:  2008-09       Impact factor: 7.141

Review 9.  Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.

Authors:  Thomas A Olson; Matthew J Murray; Carlos Rodriguez-Galindo; James C Nicholson; Deborah F Billmire; Mark D Krailo; Ha M Dang; James F Amatruda; Claire M Thornton; G Suren Arul; Sara J Stoneham; Farzana Pashankar; Daniel Stark; Furqan Shaikh; David M Gershenson; Allan Covens; Jean Hurteau; Sally P Stenning; Darren R Feldman; Peter S Grimison; Robert A Huddart; Christopher Sweeney; Thomas Powles; Luiz Fernando Lopes; Simone dos Santos Agular; Girish Chinnaswamy; Sahar Khaleel; Sherif Abouelnaga; Juliet P Hale; A Lindsay Frazier
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

10.  Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?

Authors:  Theodora Bejan-Angoulvant; Anne-Marie Bouvier; Nadine Bossard; Aurelien Belot; Valérie Jooste; Guy Launoy; Laurent Remontet
Journal:  Eur J Epidemiol       Date:  2008-02-09       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.